J.P. Morgan & Co.’s annual health care conference last month generated cautious optimism that 2026 will be a breakout year for investment in the health care and life sciences industries—particularly with artificial intelligence’s role in encouraging investment in the health ecosystem. In these Epstein Becker Green attorneys’ conversations in San Francisco, they explored the regulatory, Food and Drug Administration, and compliance issues that could affect the outlook for health care and life sciences companies this year and beyond. Here are their top takeaways.
Read the full article: AI Use Will Drive Health Care and Life Sciences Investment //
Source: https://news.bloomberglaw.com/legal-exchange-insights-and-commentary/ai-use-will-drive-health-care-and-life-sciences-investment